Are you wanting to strengthen your income portfolio with some top ASX dividend shares?
If you are, then it could be worth looking at the two named below, which have been given buy ratings and are tipped to offer generous dividend yields.
Here's what analysts are recommending to clients:
Image source: Getty Images
Amcor (ASX: AMC)
The first ASX dividend share that could be a buy according to analysts is Amcor.
It is a global packaging company that produces a wide variety of flexible and rigid packaging solutions for consumer, healthcare, and other markets.
Bell Potter is bullish on the company and has named it in its Core Portfolio. This is a diversified, benchmark aware portfolio of 25-35 Australian equities.
The broker likes the company due to its transformative merger with Berry Global, which it believes could underpin a period of significant growth. Bell Potter explains:
The investment thesis for Amcor is based on its transformative merger with Berry Global, which positions the company for a period of significant growth and quality improvement. The merger is expected to drive two years of double-digit EPS growth, fuelled by an estimated $590 million in synergies, with 80% anticipated to be realised within the first 24 months. Beyond the near-term earnings growth, the merger also creates a more resilient and less cyclical business by increasing its exposure to the defensive home & personal care and pharmaceutical sectors.
In respect to income, the consensus estimate is for dividends of 80 cents per share in FY 2026 and then 85 cents per share in FY 2027. Based on its current share price of $12.58, this would mean dividend yields of 6.3% and 6.8%, respectively.
Bell Potter doesn't currently have a price target for Amcor's shares. But a number of other brokers do, such as UBS with its buy rating and $18.25 price target.
IPH Ltd (ASX: IPH)
The team at Morgans thinks that IPH could be an ASX dividend share to buy.
It is an intellectual property company with a network of member firms working throughout 26 jurisdictions.
Although its performance hasn't been great in 2025, Morgans feels positive about its outlook and sees its current valuation as cheap. It explains:
On a like-for-like basis, IPH reported flat FY25 revenue and EBITDA -4% on pcp. Each geography recorded marginal LFL EBITDA pressure, a mix of lower filings (ANZ); cost inflation (Asia); and some temporary issues (CAD). Whilst organic growth is still challenged, the FY26 outlook for each division looks relatively stable or marginal incremental improvement. A cost out program (A$8-10m in FY26) will assist. IPH's valuation is undemanding (<10x FY26F PE), however investor patience is required given the delivery of organic growth looks to be the catalyst for a sustained re-rating.
As for income, Morgans is forecasting fully franked dividends of approximately 37 cents per share in both FY 2026 and FY 2027. Based on its current share price of $3.59, this would mean dividend yields of 10.3%.
The broker has a buy rating and $6.05 price target on its shares.
